Background: Prasugrel and ticagrelor are two novel antiplatelet agents, which have been subject to large randomized trials to compare their efficacy with clopidogrel for patients with acute coronary syndrome (ACS).
Introduction
The long-term outcome of stent placement There are, however, 2 concerns when using clopidogrel. The first is its delayed onset of action, which is due to the 2-stage activation process involving cytochrome P450
isoenzymes. 4 The second relates to the increasing evidence of a subset of patients that are clopidogrel hyporesponders or nonresponders, who are found to have delayed and/or insufficient inhibition of platelet function. The mechanism for this variable "clopidogrel resistance", also known as "high on-treatment platelet reactivity (HTPR)", is thought to be due to a number of genetic and non-genetic factors that affect the bioactivation of clopidogrel. 5, 6 An optimal inhibition of platelet function therefore cannot be guaranteed in these patients, especially in those who are carriers of the CYP2C19*2 loss-of-function polymorphism. 7 This phenomenon has commonly been associated with disastrous and life-threatening sequelae, including stent thrombosis, recurrent myocardial infarction (MI), and cardiovascular death. 4 Although relatively uncommon, this phenotype encompasses a group of patients whereby clopidogrel is not able to provide adequate platelet suppression and for whom alternative treatment options are required. Prasugrel has been shown to significantly reduce the incidence of non-fatal MI when compared with clopidogrel (7.3% vs 9.5%, p < 0.001). However, when taking into account the rates of cardiovascular death between the 2 treatment groups, it was found to be 2.4% and 2.1% respectively (p = 0.31%). Also, the rate of both fatal and nonfatal stroke between the 2 groups were found to be 1.0% and 1.0% (p = 0.93).
While it cannot be disputed that there is a significant reduction in the incidence of stent thrombosis in patients receiving prasugrel compared with clopidogrel (1.1% vs 2.4% respectively, p < 0.0001), it may be argued that the reduction in non-fatal MI cannot justify the excess rates of fatal MI and severe bleeding incurred by this change.
Similarly, there is a perceived drive to prescribe ticagrelor for either PPCI or for all ACS patients in the wake of data procured from the PLATO trial, which is supported by recent NICE guidance. 25 
Learning Points

What is already known
• The use of clopidogrel in conjunction with aspirin for patients with acute coronary syndromes (ACS) has come under scrutiny due to evidence of its varying levels of efficacy, with reports of severe and sometimes fatal outcomes.
• Two novel antiplatelet agents, prasugrel and ticagrelor, have undergone large randomized trials to compare their efficacy to clopidogrel in the TRITON TIMI-38 and PLATO trials respectively.
What this study adds
• In an indirect comparison of the PLATO and TRITON TIMI-38 trials, ticagrelor is shown to have the greater overall clinical benefit with significantly reduced mortality.
• The main indications for prasugrel use is for patients with acute STEMI, ACS patients with DM, and patients at high risk of stent thrombosis.
• The main indications for ticagrelor use is for patients with NSTEMI, patients with a history of CKD, and in those where prasugrel is contraindicated.
• Both agents have demonstrated a more consistent antiplatelet effect than clopidogrel and have shown to be effective alternatives for patients who are nonresponsive to clopidogrel therapy.
